Medical device cytotoxicity testing is a fundamental in vitro biological evaluation that determines whether a device or its materials release substances harmful to living cells. Performed in accordance with ISO 10993-5 (and its Chinese equivalent GB/T 16886.5), it is a core requirement for regulatory submissions in the European Union, the United States, China, and other major markets. This article explains the test principles, sample preparation requirements, standard test methods, acceptance criteria, and practical applications of cytotoxicity testing for medical devices.
Technical Overview
Cytotoxicity testing is an in vitro screening test that evaluates whether a medical device, or substances that leach from it, can cause cell death, inhibition of cell growth, or adverse morphological changes in cultured mammalian cells. Under the risk-based biological evaluation framework of ISO 10993-1, cytotoxicity testing is typically the first and most sensitive biological test performed on a new device or material, and it is required for almost all device categories regardless of contact duration or contact type.
- The governing international standard is ISO 10993-5, "Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity."
- The Chinese national standard GB/T 16886.5 is technically equivalent to ISO 10993-5 and is accepted for NMPA registration submissions.
- Related specifications include ISO 10993-12 for sample preparation and reference materials, and USP chapter for in vitro biological reactivity of plastics.
- Established continuous cell lines are used, most commonly L929 mouse fibroblast cells, and alternatively V79 hamster lung cells or BALB/c 3T3 cells.
- Results can be assessed qualitatively through microscopic grading of cell morphology and quantitatively through measurement of cell viability.
Because cell culture responds to a wide range of chemical leachables, including residual monomers, catalysts, plasticizers, sterilant residues, and degradation products, cytotoxicity testing serves as an early warning indicator. A cytotoxic response often triggers chemical characterization (ISO 10993-18) and toxicological risk assessment (ISO 10993-17) to identify the causative substance and guide material or process changes. Testing should be performed by accredited third-party laboratories or in-house facilities operating under an ISO/IEC 17025 compliant quality system.
Testing Samples
Finished Medical Devices
Sterile, finished devices representative of the final product, including the final manufacturing and sterilization process, are tested whenever possible. Testing the final configuration ensures that sterilization residues, mold release agents, surface treatments, and processing aids are captured in the evaluation.
Raw Materials and Polymer Compounds
Individual materials such as polymers, elastomers, metals, ceramics, and composites may be tested during early development to screen candidate materials before device integration. Material-level testing is also appropriate when a device is very large and representative coupons can be justified.
Coatings, Adhesives, and Printing Inks
Surface coatings, hydrogels, tissue adhesives, catheter lubricants, and printing inks are frequently the principal source of leachables. These components are tested either alone, applied to a representative substrate, or as part of the finished device.
Primary Packaging Materials
Packaging materials that directly contact the device, such as blister trays, films, and Tyvek-type lids, may be evaluated for cytotoxicity to confirm that no harmful substances migrate from the packaging into the device.
Sample Preparation and Extraction
Sample preparation follows ISO 10993-12. Test samples are extracted in a polar vehicle (such as serum-supplemented minimum essential medium or saline) and, when appropriate, a non-polar vehicle to capture both hydrophilic and lipophilic leachables. Common extraction ratios are based on sample thickness and geometry, for example 6 cm²/mL for materials thinner than 0.5 mm, 3 cm²/mL for thicknesses between 0.5 mm and 1 mm, and mass-based ratios of approximately 0.1 to 0.2 g/mL for irregularly shaped solids. Standard extraction conditions include 37°C for 24 hours, 50°C for 72 hours, or 70°C for 24 hours, selected to be harsher than clinical use while avoiding material degradation that would not occur in reality.
Testing Items
Cytotoxicity testing services for medical devices typically include the following evaluation items:
- In vitro cytotoxicity test, extract (elution) method, qualitative and quantitative.
- In vitro cytotoxicity test, direct contact method.
- In vitro cytotoxicity test, indirect contact method, including agar diffusion (agar overlay) and filter diffusion variants.
- Quantitative cell viability measurement using MTT, neutral red uptake (NRU), WST-1, XTT, crystal violet staining, or direct cell counting.
- Qualitative morphological grading of the cell monolayer on a reactivity scale from grade 0 (no reactivity) to grade 4 (severe reactivity).
- Verification testing with appropriate controls, including a negative control material, a positive control substance, and a blank extraction control.
The typical culture period after dosing is 24 to 48 hours, after which cells are examined microscopically and, for quantitative assays, incubated with the viability reagent and read on a spectrophotometer or plate reader. Standard negative controls include high-density polyethylene, while common positive controls include organotin compounds or nonionic surfactants that produce a defined cytotoxic response and demonstrate the sensitivity of the test system.
Testing Methods
Extract (Elution) Method
The extract method is the most widely used approach and is suitable for almost all device types. The test sample is prepared and extracted in culture medium under defined conditions, and the resulting extract is applied to a cultured cell monolayer at various dilutions. Because the device itself never touches the cells, the method evaluates only leachable substances and can be adapted to devices of any size or shape. It supports both qualitative microscopic scoring and quantitative viability endpoints.
Direct Contact Method
In the direct contact method, a portion of the test sample is placed directly onto the cell monolayer. It is best suited for low-density, non-toxic materials where leaching is limited and where sample shape permits intimate contact without mechanically damaging the cells. This method is highly sensitive because leachables diffuse directly into the culture at the contact zone, but it requires careful sample geometry control to avoid false positives caused by physical pressure.
Indirect Contact Method
The indirect contact method places a barrier between the sample and the cells. In the agar diffusion (agar overlay) test, cells are covered with a thin layer of agarose before the sample is placed on top, so that only diffusible leachables reach the cells and the zone of decolorization or lysis around the sample is scored. The filter diffusion test positions a microporous membrane between the sample and the cells. These methods are appropriate for dense materials and for devices that cannot be easily extracted.
Quantitative Viability Assays
Quantitative methods measure a metabolic or functional parameter of the cell population, such as mitochondrial reduction of the MTT tetrazolium salt to formazan, lysosomal uptake of neutral red, or total cellular protein and DNA content. Results are expressed as the percentage of viability relative to the blank control. According to ISO 10993-5, a reduction in cell viability greater than 30 percent, meaning viability below 70 percent of the blank control, indicates a cytotoxic effect. For qualitative scoring, a reactivity grade of 2 or lower is generally considered non-cytotoxic, provided controls perform as expected.
Applications
Cytotoxicity test reports from accredited third-party laboratories are used throughout the medical device lifecycle:
- Regulatory submissions to the United States FDA, including 510(k) premarket notifications and PMA applications, where in vitro cytotoxicity is a baseline biocompatibility endpoint.
- CE marking under the European Medical Device Regulation (EU MDR), where cytotoxicity results feed into the biological evaluation plan and biological safety file.
- NMPA registration in China under GB/T 16886.5, including registration dossiers for Class II and Class III devices.
- Submissions to other jurisdictions, including Japan, South Korea, Canada, Brazil, and Australia, which recognize ISO 10993-based biological evaluation data.
- Research and development screening of new biomaterials, additives, and surface treatments before committing to device-level biocompatibility programs.
- Change control evaluation after modifications to materials, suppliers, manufacturing processes, sterilization methods, or primary packaging.
- Periodic verification and batch-related quality control where a biological safety margin must be demonstrated.
As part of a complete ISO 10993-1 evaluation, cytotoxicity data is typically combined with irritation and sensitization testing (ISO 10993-10 and ISO 10993-23), systemic toxicity studies (ISO 10993-11), and, where applicable, hemocompatibility, genotoxicity, and implantation testing. A passing cytotoxicity result alone does not demonstrate full biological safety; it is one pillar of an integrated biological risk assessment.
FAQ
What is medical device cytotoxicity testing?
It is an in vitro laboratory test that exposes cultured mammalian cells, typically L929 mouse fibroblasts, to a medical device, its material, or an extract of the device, and evaluates whether cell death, growth inhibition, or morphological damage occurs. It detects harmful leachable substances and is the most frequently required biocompatibility test worldwide.
Which standards govern cytotoxicity testing?
The primary standard is ISO 10993-5 for the test method and evaluation criteria, supported by ISO 10993-12 for sample preparation and extraction. In China, the equivalent national standard is GB/T 16886.5. Accredited third-party laboratories report against these standards for global submissions.
What are the pass criteria for ISO 10993-5 cytotoxicity testing?
For qualitative assessment, the test sample should show a reactivity score of grade 2 or less (on a 0 to 4 scale) and should not exceed the response allowed by the validation scheme. For quantitative assessment, cell viability must be at least 70 percent of the blank control; viability below 70 percent indicates a cytotoxic effect requiring investigation.
How much sample is needed for testing?
Sample quantity depends on the device and the extraction ratio. Typical requirements range from 4 to 120 square centimeters of material surface, or the equivalent mass for irregular items, per extraction vehicle. Sterile samples in their final finished state should be provided whenever possible, and laboratories can advise on coupon preparation for large or multi-material devices.
How long does a cytotoxicity test take?
The core test, from cell seeding through final reading, generally takes about one to two weeks, with standard reporting turnaround of seven to fifteen working days after sample receipt, depending on the method selected, the number of extraction vehicles, and whether qualitative or quantitative endpoints are required.
How do I choose between the extract, direct contact, and indirect contact methods?
The extract method is the default choice for most devices because it works for any shape and captures diffusible leachables. Direct contact suits flat, non-cytotoxic, low-leaching materials, while agar or filter diffusion suits dense materials and devices that cannot be practically extracted. The rationale for method selection should be documented in the biological evaluation plan.
What happens if my device fails the cytotoxicity test?
A failure triggers an investigation that may include chemical characterization of the extract (ISO 10993-18), review of residuals from manufacturing and sterilization, and toxicological risk assessment (ISO 10993-17). Corrective actions often involve material substitution, improved post-curing or cleaning, or a change in sterilization modality, followed by retesting.
Does a cytotoxicity test replace other biocompatibility tests?
No. Cytotoxicity is only the initial screen of the ISO 10993-1 evaluation matrix. Depending on the nature of body contact and contact duration, additional endpoints such as sensitization, irritation, systemic toxicity, hemocompatibility, genotoxicity, and implantation testing are usually required for full regulatory acceptance.